Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.

Br J Cancer · 2005 · PMC2361950 · PMID 15756271

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a small trendno p-value reported

No significant between-group differences for any adverse events were seen, although there was a small trend towards better tolerability in Group B.

also in 722 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.